Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

s retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients and in February 2009 Anadys initiated dosing in a 14 day study in healthy volunteers.

In an earlier Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. All reported adverse events were classified as mild or moderate, with no apparent dose relationship. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 consistent with the potential for once-daily or twice-daily oral dosing.

In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598.

If ANA598 is successful in early stage development, the Company anticipates completion of the clinical, toxicology and manufacturing activities required to initiate Phase II studies of ANA598 in combination with current standard of care in mid-2009.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting ap
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- ,, Reportlinker.com announces that a new ... catalogue: ,, Hepatitis B Vaccines - ... ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ,, Hepatitis ... Forecasts to 2015 ,, Summary ... report, "Hepatitis B Vaccines - Pipeline Analysis ...
(Date:12/15/2009)... Dec. 15 Reportlinker.com announces that ... in its catalogue: ,, Boehringer Ingelheim ... ,, Introduction ,, This ... for Boehringer Ingelheim in the Rx pharmaceutical ... and pipeline analysis and assessment of financial ...
(Date:12/15/2009)... 15 Waters Corporation (NYSE: ... (v.7.1 SR4), an electronic laboratory notebook solution for ... secure electronic repository that stores and manages all ... and is used to boost efficiency in life ... SAFE-BioPharma digital identity and signature standard. The SAFE-BioPharma ...
Breaking Medicine Technology:Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 2Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 3Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 4Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 5Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 6Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient 13365 1Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient 13365 2The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 1The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 2The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 3The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 4The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 5The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 6The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 7The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 8The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 9The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 10The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 11The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 12Perrigo Company Will Release Fiscal Year 2009 Results on August 18 2009 53672 1
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
... in Nonclinical (IND) In- Vitro,Studies for Promising ... (PRIME NEWSWIRE) -- Samaritan,Pharmaceuticals Inc. (AMEX:LIV), a ... positive results were attained with its,late-stage preclinical/nonclinical ... models. , Although nonclinical research results are ...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 2Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 3
(Date:12/15/2009)... bizarre about-face, the secretive Central Intelligence Agency has requested documents ... obtained them from the CIA itself under the Freedom of ... ... December 15, 2009 -- In a bizarre about-face, the secretive ... even though the writer had earlier obtained them from the ...
(Date:12/15/2009)... Management Systems (HRMS), announced in a direct response to demand ... (APSS) to its suite of HR software, to increase productivity ... ... Mahwah, NJ (PRWEB) December 15th 2009 -- Humanic ... announced in a direct response to demand for increased technology ...
(Date:12/15/2009)... is deemed safer than wood fiber , , TUESDAY, Dec. 15 ... an arm in a fall are much lower on playgrounds ... surfaces, new research has found. , Researchers at the Hospital ... had playground surfaces of either granite sand or engineered wood ... PLoS Medicine . , The risk of a broken arm ...
(Date:12/15/2009)... for inflammatory marker may spot people in need of ... -- People with normal levels of LDL (bad) cholesterol ... inflammation in order to identify those who may benefit ... of heart attack, stroke and death, say U.S. researchers. ... JUPITER trail, which showed that statins can prevent heart ...
(Date:12/15/2009)... – Delicious Planet, Seattle’s premier organic meal delivery service ( ... its Delicious Planet Detox Program, Randi Carter, company founder and ... ... (December 15, 2009 – Seattle, WA) – Delicious Planet, Seattle’s ... orders now for the launch of its Delicious Planet Detox ...
Breaking Medicine News(10 mins):Health News:CIA Requests its Own Documents from Author 2Health News:CIA Requests its Own Documents from Author 3Health News:Humanic Design is Pleased to Announce Application Self Service (APSS) to its Product Suite to Empower Organizations with Automation 2Health News:Normal Cholesterol Doesn't Guarantee Healthy Heart 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 4
... Church Team Up to Transport Goods to Peru, ... today,teamed up with its largest customer, DHL, to provide ... of Jesus Christ of Latter-day,Saints to help those injured ... Peru, on August 15, 2007. The 67,000 pounds of,specially ...
... the leading ... mortality, BETHESDA, Md., Sept. 28 With the recent ... and the U.S.,Senate to create a national clinical trials network ... a two-day,summit to work toward reducing or eliminating barriers to ...
... the condition, study says , , FRIDAY, Sept. 28 (HealthDay News) ... or after pregnancy, a new study finds. , The consequences ... and her entire family, according to the report in the ... . , "The prevalence of women diagnosed with depression before, ...
... FAIRFIELD, N.J., Sept. 28 Bradley,Pharmaceuticals, Inc. (NYSE: ... division will feature Elestrin(TM) (estradiol gel 0.06%) at,the ... Meeting to,be held in Dallas, Texas from October ... dose transdermal estrogen therapy,available by prescription, for the ...
... cheering and,famous Chicago chefs watching their every move, the ... Consorta,s Battle of the Hospital,Chefs. Chef William Read, ... the patients at Saint Mary,s Health Care in Grand ... becoming the reigning champion of,chefs among the nearly 550 ...
... newly identified debilitating and painful condition that affects patients ... and hardening of the skin. It usually affects the ... organs and can progress so rapidly that patients can ... it is not clear what causes NSF, the condition ...
Other Medicine News:Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 2Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 3Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting 2Health News:Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting 3Health News:Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting 4Health News:Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting 5Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2Health News:Higher death rates in kidney patients with newly recognized disease 2Health News:Higher death rates in kidney patients with newly recognized disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: